SEARCH

SEARCH BY CITATION

References

  • 1
    Manolio TA, Brooks LD, Collins FSA. HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008; 118: 1590605.
  • 2
    Feero GW, Guttmacher AE, Collins FS. Genomic medicine – an updated primer. N Engl J Med 2010; 362: 200111.
  • 3
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 4
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature 2009; 461: 399401.
  • 5
    McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 230714.
  • 6
    Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 4: 34450.
  • 7
    Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 337.
  • 8
    Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 11004.
  • 9
    Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 133845.
  • 10
    Yasuhito T, Nao N, Masaya S, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 11059.
  • 11
    Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy–a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 11907.
  • 12
    Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798801.
  • 13
    Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 158692.
  • 14
    Beinhardt S, Aberle JH, Strasser M, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012; 142: 7885.
  • 15
    Duggal P, Thio CL, Wojcik GL, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Int Med 2013; 158: 23545.
  • 16
    Ashraf S, Nitschke K, Warshow UM, et al. Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection. Hepatology 2013; 58: 8819.
  • 17
    Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunol 2003; 4: 638.
  • 18
    Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 45019.
  • 19
    Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006; 26: 3739.
  • 20
    Onoguchi K, Yoneyama M, Takemura A, et al. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007; 282: 757681.
  • 21
    Kotenko SV, Gallagher G, Baurin VV, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 6977.
  • 22
    Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499509.
  • 23
    Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with different expression of intrahepatic interferon stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 188896.
  • 24
    Abe H, Hayes CN, Ochi H, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 6: 1094101.
  • 25
    Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Gen 2013; 45: 16471.
  • 26
    Aka P, Kuniholm MH, Pfeiffer RM, et al. Association of the IFNL4-ΔG Allele with Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis 2014; 209: 3504.
  • 27
    Honda M, Shirasaki T, Shimakami T, et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 2014; 59: 82838.
  • 28
    Hamming OJ, Terczynska-Dyla E, Vieyres G, et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO 2013; 32: 305565.
  • 29
    Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, et al. Polymorphisms of interferon-λ4 and IL28B – effect on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014; 39: 10411.
  • 30
    Covolo L, Bibert S, Donato F, et al. The novel ss469415590 variant predicts virologic response to therapy in patients with genotype 1 infection. Aliment Pharmacol Ther 2014; 39: 32230.
  • 31
    Horner SM, Gale M Jr. Regulation of innate hepatic immunity by hepatitis C virus. Nat Med 2013; 19: 87988.
  • 32
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32: 88102.
  • 33
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 34
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 35
    Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 60818.
  • 36
    Jacobson IM, Calett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54(Suppl.): S5423.
  • 37
    Pol S, Aerssens J, Zeuzem S, et al. Limited impact of IL28B genotype onresponse rates in telaprevir-treated patients with prior treatment failure. J Hepatol 2013; 58: 8839.
  • 38
    Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58(Suppl. 1): S574.
  • 39
    Manns M, Marcellin P, Pordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58(Suppl. 1):S568.
  • 40
    Forns X, Lawitz E, Zeuzem S, et al. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. Hepatology 2013; 58 (S1): 138A.
  • 41
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 187887.
  • 42
    Chu TW, Kulkarni R, Gane EJ, et al. Effect of IL28B on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 7905.
  • 43
    Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 6309.
  • 44
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 21121.
  • 45
    Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370: 22232.
  • 46
    Jacobson IM, Gordon SC, Kowdley KV, et al. Sofobuvir for hepatitis genotype 2 and 3 in patients without treatment options. N Engl J Med 2013; 368: 186877.
  • 47
    Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; doi: 10.1093/infdis/jit827 [Epub ahead of print].
  • 48
    Noureddin M, Wright EC, Alter H, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58: 154857.
  • 49
    White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 83144.
  • 50
    Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 72331.
  • 51
    Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 28805.
    Direct Link:
  • 52
    Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 163642.
  • 53
    Li JH, Lao XQ, Tillmann HL, et al. Interferonlambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 190411.
  • 54
    Stättermayer AF, Rutter K, Beinhardt S, et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57: 4928.
  • 55
    Bronowicki JP, Hezode C, Bengtsson L, Pol S, et al. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. J Hepatol 2012; 56(Suppl. 2): S4301.
  • 56
    Beinhardt S, Payer BA, Datz C, et al. A prognostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol 2013; 59: 9727.
  • 57
    Gutierrez JA, Parikh N, Branch AD. Classical and emerging roles of vitamin D in hepatitis C virus infection. Sem Liver Dis 2011; 31: 38798.
  • 58
    García-Martín E, Agúndez JA, Maestro ML, et al. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. PLoS ONE 2013; 8: e74764.
  • 59
    Wilson PA, Gardner SD, Lambie NM, et al. Characterization of the human patatin-like phospholipase family. J Lipid Res 2006; 47:19409.
  • 60
    Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA 2010; 107: 78927.
  • 61
    Jenkins CM, Mancuso DJ, Yan W, et al. Identification, cloning, expression, and purification three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004; 279: 4896875.
  • 62
    Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 14615.
  • 63
    Tian C, Stokowski RP, Kershenobich D, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2009; 42: 213.
  • 64
    Trepo E, Guyot E, Ganne-Carrie N, et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012; 55: 13078.
  • 65
    Nischalke HD, Berger C, Luda C, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS ONE 2011; 6: e27087.
  • 66
    Trepo E, Nahon P, Bontempi G, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a metaanalysis of individual participant data. Hepatology 2013; doi: 10.1002/hep.26767 [Epub ahead of print].
  • 67
    Trepo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 609.
  • 68
    Cai T, Dufour JF, Muellhaupt B, et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 2011; 55: 52935.
  • 69
    Valenti L, Aghemo A, Stättermayer AF, et al. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 2012; 35: 143442.
  • 70
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 71
    Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13: 33517.
  • 72
    Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 70516.
  • 73
    Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 183950.
  • 74
    Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 43441.
  • 75
    Rutter K, Ferlitsch A, Maieron A, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis c patients with advanced liver disease – predictive factors for sepsis. J Hep 2013; 58(Suppl. 1): S30.
  • 76
    De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 9971004.
  • 77
    Thompson AJ, Santoro R, Piazzolla V, et al. Inosinetriphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011; 53: 38995.
  • 78
    Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111: 3607.
  • 79
    Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet 2002; 47: 6202.
  • 80
    Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C>A and g.IVS2 + 21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta 2007; 1772: 96102.
  • 81
    Stepchenkova EI, Tarakhovskaya ER, Spitler K, et al. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol 2009; 392: 60213.
  • 82
    Hitomi Y, Cirulli ET, Fellay J, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011; 140: 131421.
  • 83
    Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 4058.
  • 84
    Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy–a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 11907.
  • 85
    Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139: 11819.
  • 86
    Eskesen AN, Melum E, Moghaddam A, et al. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol 2012; 24: 8906.
  • 87
    Seto WK, Tsang OT, Liu K, et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J Viral Hepat 2013; 20: 4707.
  • 88
    Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 41521.
  • 89
    Ogawa E, Furusyo N, Nakamuta M, et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol 2013; 59: 66774.
  • 90
    Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 8493.
  • 91
    Scherzer TM, Stättermayer AF, Stauber R, et al. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol 2013; 59: 96471.
  • 92
    Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19: 85968.
  • 93
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 11048.
  • 94
    EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 16785.
  • 95
    Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699705.
  • 96
    Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 20029.
  • 97
    Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 1239.
  • 98
    van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 80410.
  • 99
    Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol 2013; 58: 898903.
  • 100
    Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142: 51320.
  • 101
    Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology 2013; 57: 8906.
  • 102
    Wu X, Xin Z, Zhu X, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012; 93: 297300.
  • 103
    Seto WK, Wong DK, Kopaniszen M, et al. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695703.
  • 104
    Holmes JA, Nguyen T, Ratnam D, et al. IL28B genotype is not useful for predicting treatment outcomes in Asian chronic hepatitis B patients treated with pegylated-interferon-α. J Gastroenterol Hepatol 2013; 28: 8616.
  • 105
    de Niet A, Takkenberg RB, Benayed R, et al. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol 2012; 47: 47581.
  • 106
    Zhang Q, Lapalus M, Asselah T, et al. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2013; doi: 10.1111/jvh.12177 [Epub ahead of print].
  • 107
    Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2011; 16: 62937.
  • 108
    Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 5915.
  • 109
    Nishida N, Sawai H, Matsuura K, et al. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS ONE 2012; 7: e39175.
  • 110
    Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the HanChinese population. Hepatology 2011; 53: 4228.
  • 111
    Hu L, Zhai X, Liu J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 2012; 55: 142631.
  • 112
    Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2011; 16: 62937.
  • 113
    Ryder LP, Svejgaard A, Dausset J. Genetics of HLA disease association. Annu Rev Genet 1981; 15: 16987.
  • 114
    Al-Qahtani A, Khalak HG, Alkuraya FS, et al. Genome-wide association study of chronic hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3. J Med Genet 2013; 50: 72532.